



R^{12} is independently selected from: OH, CN, and C_{1-4} alkoxy.

6. A compound according to any of claims 1 to 5, wherein:

X is O;

ring A is ;

ring B is independently selected from: , , , and ;

R^2, at each occurrence, is independently selected from: halogen, C_{1-4} alkyl substituted with 0-1 R^{12}, C_{1-4} alkoxy, and benzyl;

R^3 is independently selected from: CN, C_{1-4} haloalkyl, 4-halo-Ph, 4-CN-Ph, 4-CO_2(C_{1-2} alkyl)-Ph, 2-halo-4-CN-Ph, 3-halo-4-halo-Ph, 3-CN-4-CN-Ph, and pyrimidinyl;

R^4 is independently C_{1-4} alkyl or -CH_2-C_{3-6} cycloalkyl;

R^5 is independently halogen or C_{1-4} alkyl;

R^6, at each occurrence, is independently selected from: halogen, CN, C_{1-4} alkyl, C_{1-4} alkoxy, cyclopentoxy, and oxazolyl; and

R^{12} is independently selected from: OH, CN, and C_{1-4} alkoxy.

7. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of any one of claims 1 to 6, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

8. The use of the pharmaceutical composition according to claim 7, in the manufacture of a medicament for the treatment of heart failure and peripheral arterial disease, the pharmaceutical

composition further comprising one or more other suitable therapeutic agents ~~useful in the treatment of the aforementioned disorders~~ including: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, anti-pancreatic agents, lipid lowering agents, anorectic agents, memory enhancing agents, anti-dementia agents, cognition promoting agents, appetite suppressants~~, treatments for heart failure, treatments for peripheral arterial disease~~ and anti-inflammatory agents.

9. The pharmaceutical composition according to claim 7, further comprising a dipeptidyl peptidase-IV inhibitor and/or a sodium-glucose transporter-2 inhibitor.

10. The use of a~~A~~ compound of any one of claims 1 to 6 in the manufacture of a medicament for ~~use in~~the prevention~~ng~~, modulation~~ng~~ or treatment~~ing~~ of diabetes, hyperglycemia, impaired glucose tolerance, gestational diabetes, insulin resistance, hyperinsulinemia, retinopathy, neuropathy, nephropathy, diabetic kidney disease, acute kidney injury, cardiorenal syndrome, acute coronary syndrome, delayed wound healing, atherosclerosis and its sequelae, abnormal heart function, congestive heart failure, myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, fatty liver disease, dislipidemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low high-density lipoprotein (HDL), high low-density lipoprotein (LDL), non-cardiac ischemia, pancreatitis, lipid disorders, neurodegenerative disease, cognitive impairment, dementia, and liver diseases such as NASH (Non-Alcoholic SteatoHepatitis), NAFLD (Non-Alcoholic Fatty Liver Disease) and liver cirrhosis.

11. A compound for use according to claim 10, wherein the compound of any one of of claims 1 to 6 is used simultaneously, separately or sequentially with an additional therapeutic agent.